These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Designing better drugs: predicting cytochrome P450 metabolism. de Groot MJ Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528 [TBL] [Abstract][Full Text] [Related]
6. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Dong D; Wu B Drug Metab Rev; 2012 Feb; 44(1):1-17. PubMed ID: 22242930 [TBL] [Abstract][Full Text] [Related]
7. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach. Korolev D; Balakin KV; Nikolsky Y; Kirillov E; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Nikolskaya T J Med Chem; 2003 Aug; 46(17):3631-43. PubMed ID: 12904067 [TBL] [Abstract][Full Text] [Related]
8. Predicting the binding modes and sites of metabolism of xenobiotics. Mukherjee G; Lal Gupta P; Jayaram B Mol Biosyst; 2015 Jul; 11(7):1914-24. PubMed ID: 25913019 [TBL] [Abstract][Full Text] [Related]
9. A pragmatic approach using first-principle methods to address site of metabolism with implications for reactive metabolite formation. Hsiao YW; Petersson C; Svensson MA; Norinder U J Chem Inf Model; 2012 Mar; 52(3):686-95. PubMed ID: 22299574 [TBL] [Abstract][Full Text] [Related]
10. Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. Mishra NK; Agarwal S; Raghava GP BMC Pharmacol; 2010 Jul; 10():8. PubMed ID: 20637097 [TBL] [Abstract][Full Text] [Related]
11. Molecular Docking Supplements an In vitro Determination of the Leading CYP Isoform for Arylpiperazine Derivatives. Ulenberg S; Bączek T; Zieliñska J; Belka M; Król M; Herold F Comb Chem High Throughput Screen; 2019; 22(6):370-378. PubMed ID: 31284855 [TBL] [Abstract][Full Text] [Related]
12. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Crivori P; Poggesi I Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065 [TBL] [Abstract][Full Text] [Related]
13. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity. Lewis DF; Ito Y Xenobiotica; 2009 Aug; 39(8):625-35. PubMed ID: 19514836 [TBL] [Abstract][Full Text] [Related]
14. Prediction of amino acid residues participated in substrate recognition by cytochrome P450 subfamilies with broad substrate specificity. Zharkova MS; Sobolev BN; Yu Oparina N; Veselovsky AV; Archakov AI J Mol Recognit; 2013 Feb; 26(2):86-91. PubMed ID: 23334916 [TBL] [Abstract][Full Text] [Related]
15. QNA-Based Prediction of Sites of Metabolism. Tarasova O; Rudik A; Dmitriev A; Lagunin A; Filimonov D; Poroikov V Molecules; 2017 Dec; 22(12):. PubMed ID: 29194399 [TBL] [Abstract][Full Text] [Related]
16. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Zhou SF; Liu JP; Chowbay B Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967 [TBL] [Abstract][Full Text] [Related]
17. Combining structure- and ligand-based approaches to improve site of metabolism prediction in CYP2C9 substrates. Kingsley LJ; Wilson GL; Essex ME; Lill MA Pharm Res; 2015 Mar; 32(3):986-1001. PubMed ID: 25208877 [TBL] [Abstract][Full Text] [Related]